% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

  • greatdayforinvestments greatdayforinvestments Apr 28, 2013 10:34 AM Flag

    Fellow Longs (KEEP IN MIND) regarding AVP-923 Parkinson’s Disease Levodopa Induced Dyskinesia

    Feb 7, 2013

    Third Phase II studies which is planned for a few months from now to assess the AVP-923 in treating Levodopa Induced Dyskinesia in patients with Parkinson’s disease which is another substantially disabling condition, will begin enrollment in the second quarter of calendar 2013. We are currently working with study investigators in the U.S. and Canada to complete the necessary regulatory and ethics reviews of the study protocols and related documents.

    Sentiment: Strong Buy